MEIYOUHENG Wins NMPA Approval as World’s First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma
I'm PortAI, I can summarize articles.
TOT BIOPHARM, in collaboration with BioDlink and Lepu Biopharma, has received NMPA approval for MEIYOUHENG®, the first EGFR-targeting ADC drug. This marks a significant milestone as the first ADC fully manufactured by a CDMO to reach the Chinese market, showcasing advancements in the biopharmaceutical sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments